Clear Street Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)
Tweet Send to a Friend
Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $108.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


